General safety of moxifloxacin

Formulary

Volumn 37, Issue SUPPL. 3, 2002, Pages 32-35

  Iannini, Paul B ^a  

^a DANBURY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTACID AGENT; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; CLINDAMYCIN; DIGOXIN; DIURETIC AGENT; ENOXACIN; FUROSEMIDE; GATIFLOXACIN; GLIBENCLAMIDE; GREPAFLOXACIN; LEVOFLOXACIN; METOPROLOL; METOPROLOL TARTRATE; MOXIFLOXACIN; OFLOXACIN; PEFLOXACIN; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE; SPARFLOXACIN; TEMAFLOXACIN; THEOPHYLLINE; TOSUFLOXACIN; TROVAFLOXACIN; UNINDEXED DRUG; WARFARIN;

ANIMAL MODEL; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG MONITORING; DRUG SAFETY; HEADACHE; HEMOLYTIC UREMIC SYNDROME; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; NAUSEA; NONHUMAN; PSEUDOMEMBRANOUS COLITIS; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; TORSADE DES POINTES; TREATMENT OUTCOME; VASCULITIS; VERTIGO; VOMITING;

EID: 0036279012     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Profile of moxifloxacin drug interactions
2. Clinical pharmacology
3. Effect of norfloxacin on theophylline disposition: A comparison with other fluoroquinolones
4. Clinically significant pharmacokinetic interactions between dietary caffeine and medications
5. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers
6. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans
7. Safety update of moxifloxacin: A current review of clinical trials and post-marketing observational studies
8. Incidence of diarrhea and colitis associated with clindamycin therapy
9. Comparative toxicities of third-generation cephalosporins
10. History of quinolones and their side effects
11. Pefloxacin-induced Achilles tendon toxicity in rodents: Biochemical changes in proteoglycan synthesis and oxidative damage to collagen
12. Levofloxacin-induced bilateral Achilles' tendonitis
13. Arthropathy secondary to ciprofloxacin in an adult cystic fibrosis patient
14. Pefloxacin-induced arthropathy in an adolescent with brain abscess
15. Ciprofloxacin-induced hypersensitivity vasculitis
16. Ofloxacin-induced vasculitis
17. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
18. Possible epidemiological factors associated with rupture of the posterior tibial tendon
19. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin
20. Diagnosis of quinolone-induced arthropathy in juvenile dogs by use of magnetic resonance (MR) imaging
21. Magnetic resonance imaging in children receiving quinolones: No evidence of quinolone-induced arthropathy. A multicenter survey
22. Ciprofloxacin use: Acute arthropathy and long-term follow-up
23. La tachycardia ventriculaire a deux foyers opposes variables
24. Correction of the QT interval for heart rate: Review of different formulas and the use of Bazett's formula in myocardial infarction
25. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics
26. Moxifloxacin: Clinical efficacy and safety
27. QTc prolongation associated with levofloxacin
28. Moxifloxacin has a favorable cardiovascular safety profile in patients taking concomitant QTc prolonging drugs
29. Safety of gatifloxacin in patients with a history of cardiovascular disease
30. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes
31. Evaluating the risk of cardiac toxicity